Connor, Clark & Lunn Investment Management (CC&L)
TRIL

Connor, Clark & Lunn Investment Management (CC&L)’s Trillium Therapeutics Inc. TRIL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,200
Closed -$355K – 1263
2021
Q3 		$355K Sell
20,200
-322,300
-94% -$3.77M ﹤0.01% 838
2021
Q2 		$3.32M Sell
342,500
-27,400
-7% -$258K 0.02% 442
2021
Q1 		$3.96M Buy
369,900
+169,400
+84% +$2.1M 0.02% 411
2020
Q4 		$2.95M Buy
+200,500
New +$2.89M 0.02% 431

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TRIL Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,200 shares — an estimated $355K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TRIL in Q4 2020 and held it in 4 quarters. The position peaked at $3.96M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 20,200 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $355K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Trillium Therapeutics Inc. position peaked at $3.96M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.